Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

(2010) D. J. Drucker et al.   DIABETES CARE

Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis

(2010) R. Garg et al.   DIABETES CARE

Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions With Metformin

(2009) A. V. Matveyenko et al.   DIABETES

Exenatide-Associated Ischemic Renal Failure

(2009) W. J. Weise et al.   DIABETES CARE

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

(2009) J. S. Nachnani et al.   DIABETOLOGIA

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use

(2008) D. P. Kao et al.   DIABETIC MEDICINE